Diabetes · Phase 3
Mazdutide versus dulaglutide: diabetes in China
What was tested?
Mazdutide compared with dulaglutide in Chinese adults with type 2 diabetes inadequately controlled on oral glucose-lowering medicines. ↗
Registered primary question: Change in HbA1c from baseline to week 28. ↗
What the reviewed report found
Journal year 2026 · Article summary reviewed 2026-09-15
Between-group HbA1c differences favored the two mazdutide groups by 0.24 and 0.30 percentage points; reductions in percentage body-weight change were 3.78 and 5.76 percentage points greater than with dulaglutide. Gastrointestinal events were more frequent with mazdutide.↗
Keep in context: This active-comparator trial concerns selected treatment groups in a specified diabetes population. It does not rank the drugs across other conditions, treatment settings or long-term outcomes. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 731 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2024-08-23; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Type 2 diabetes: active comparator
- Design in the report
- Randomized phase 3 comparison with a specified dulaglutide regimen over 28 weeks.↗
- Participants in the report
- 731 adults in China with type 2 diabetes participated.↗
- Limitations
- The comparison is specific to the tested regimens and population, not a ranking against all uses of the comparator or other medicines.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study of IBI362 in Participants With Type 2 Diabetes ↗
Protocol identifier: CIBI362A302. Sponsor: Innovent Biologics (Suzhou) Co. Ltd..
Retrieved 2026-09-20; SHA-256 dd46d03b252f91f335957eb43059b48d1ef1417ba193870ccb86760106aec69b.
PMID 41407860
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 41407860. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 96659a8cb3d822294b045d64391e17389e263cdb8d0d5df526d0d74511a52487.